Contineum Therapeutics Inc (CTNM) Actualités

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

- Phase 1b trial will evaluate receptor occupancy of PIPE-791 in the brain and lungs of patients in multiple cohorts using a PET tracer of the...

Form 4 - Statement of changes in beneficial ownership of securities

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

- Phase 1b study for the potential treatment of osteoarthritis and low back pain expected to commence in the first quarter of 2025 - Initial data...

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

-Enrollment for PIPE-307 VISTA trial on track- -Strong cash position of $214 million at the end of Q3 expected to support operations through...

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report